Analyst Expectations for Marinus Pharma's Future
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 5 Wall Street analysts have provided ratings for Marinus Pharma (NASDAQ:MRNS), with 3 being bullish and 2 somewhat bullish. There have been no indifferent, somewhat bearish, or bearish ratings. The average 12-month price target for MRNS is $25.6, with a high of $28.00 and a low of $21.00. This target has decreased by 1.54% from the previous target of $26.00. Analyst ratings are important as they provide investors with specialized advice on stock performance, though they may be subject to error.
December 05, 2023 | 6:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Marinus Pharma received positive ratings from analysts, with an average price target of $25.6, which is a slight decrease from the previous target. The overall sentiment is bullish.
The positive ratings from analysts, with no bearish or even neutral opinions, suggest a strong bullish sentiment towards MRNS. However, the slight decrease in the average price target may temper the short-term impact on the stock price. The importance is rated at 75 because analyst ratings are influential but not the only factor affecting stock prices. The confidence level is at 80, acknowledging the general accuracy of analyst ratings but also their potential for error.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100